Clever Culture Systems (CC5) investor relations material

Executive summary

• Three APAS Independence instruments sold, installed and invoiced in Q1 FY27: two to Novo Nordisk and one to AstraZeneca; H1 sales and evaluations are expected to reach 8 units.

• Commercial strategy centers on global pharmaceutical manufacturers, combining direct land-and-expand sales with a new PSC Biotech channel in the US, Canada and Singapore.

Financial highlights

• Cash and cash equivalents were $1.405 million at 30 September 2026; quarterly net cash used in operating activities was $317,000 and investing activities used $12,000.

• Customer receipts were $1.486 million and government grants and tax incentives provided $770,000 in the quarter.

• Reported total net cash outflows were $0.3 million; cash outflows included $2.6 million in expenditures, including the usual $1.6 million quarterly cost base and $1.0 million for inventory, sales-related costs and corporate costs.

Outlook and guidance

• H1 FY27 sales and new evaluations are expected to reach 8 units, matching FY26 sales and providing a foundation for a potential step-change in FY27 sales.

• Purchase orders from two existing global pharmaceutical customers are expected in Q2 FY27, with invoicing also expected in that quarter, subject to completion of procurement discussions.

• A new single-site pharmaceutical manufacturer is in final purchase-commitment discussions, with installation and qualification planned before calendar year-end 2026.

• A paid evaluation with a new Top-20 global pharmaceutical company is expected to commence in Q2 FY27.